Regeneron Announces Presentation at the 40th Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Regeneron Pharmaceuticals (NASDAQ: REGN) will present at the 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022, at 10:30 a.m. ET. The presentation will be available via webcast on Regeneron's website, with an archived version accessible for 30 days. Regeneron focuses on developing life-transforming medicines, having nine FDA-approved treatments and several candidates in the pipeline. Its proprietary technologies, including VelociSuite, enhance drug development processes, while the Regeneron Genetics Center leads extensive genetic sequencing initiatives.

Positive

• Regeneron has developed nine FDA-approved treatments.
• The company is utilizing proprietary VelociSuite technologies to enhance drug development.
• Regeneron Genetics Center is conducting one of the largest genetic sequencing efforts globally.

Negative

• None.

TARRYTOWN, N.Y., Dec. 22, 2021 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast its presentation at the 40^th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022.  The presentation is scheduled for 10:30 a.m. Eastern Time and may be accessed from the "Investors & Media" page of Regeneron's website at http://investor.regeneron.com/events-and-presentations.  An archived version of the presentation will be available for at least 30 days.

About Regeneron
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for over 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to nine FDA-approved treatments and numerous product candidates in development, almost all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic conditions, infectious diseases and rare diseases.

Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite^® technologies, such as VelocImmune^®, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center, which is conducting one of the largest genetics sequencing efforts in the world.

For additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter.

Contact Information:
Investor Relations
Mark Hudson
914.847.3482
mark.hudson@regeneron.com

Corporate Communications
Christina Chan
914.847.8827
christina.chan@regeneron.com

View original content:https://www.prnewswire.com/news-releases/regeneron-announces-presentation-at-the-40th-annual-jp-morgan-healthcare-conference-301449888.html

SOURCE Regeneron Pharmaceuticals, Inc.

FAQ

When is Regeneron presenting at the J.P. Morgan Healthcare Conference?

Regeneron will present on January 10, 2022, at 10:30 a.m. ET.

How can I access Regeneron's presentation from the J.P. Morgan Healthcare Conference?

The presentation can be accessed via webcast on Regeneron's 'Investors & Media' page.

What is Regeneron Pharmaceuticals known for?

Regeneron is known for inventing life-transforming medicines and has nine FDA-approved treatments.

What technologies does Regeneron use in drug development?

Regeneron uses proprietary technologies including VelociSuite to accelerate drug development.

What initiatives is Regeneron involved in?

Regeneron is involved in extensive genetic sequencing through the Regeneron Genetics Center.